Candel Therapeutics, Inc. CADL Total Liabilities
Total Liabilities at other companies
Other financials
Where this comes from
Reported directly by Candel Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:Liabilities.
The official record: Candel Therapeutics, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Candel Therapeutics, Inc.'s total liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Candel Therapeutics, Inc.'s total liabilities?
- Candel Therapeutics, Inc. (CADL) reported total liabilities of $63.89M in Q1 2026.
- How has Candel Therapeutics, Inc.'s total liabilities changed year-over-year?
- Candel Therapeutics, Inc.'s total liabilities increased by 200.9% year-over-year, from $21.23M to $63.89M.
- What is the long-term trend for Candel Therapeutics, Inc.'s total liabilities?
- Over 5 years (2020 to 2025), Candel Therapeutics, Inc.'s total liabilities has grown at a 41.8% compound annual growth rate (CAGR), from $12.78M to $73.27M.
- What does total liabilities mean?
- The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.